Gritstone bio Inc
Change company Symbol lookup
Select an option...
GRTS Gritstone bio Inc
ADBE Adobe Inc
GBTC Grayscale Bitcoin Trust (BTC)
GPN Global Payments Inc
BAC Bank of America Corp
BSRR Sierra Bancorp
MSI Motorola Solutions Inc
ESI Element Solutions Inc
INVZW Innoviz Technologies Equity Warrant Exp 05 April 2026 *W EXP 04/05/2026
BEN Franklin Resources Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Gritstone bio, Inc. is a biotechnology company. The Company discover, develop, manufacture and deliver next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The Company has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate that are collaborating on with Gilead Sciences, Inc. The Company’s product candidates include GRT-C907 (ChAd)/R908 (samRNA), GRT- C909 (ChAd)/R910 (samRNA), GRT-C909 (ChAd)/R910 (samRNA), GRT-R914 (samRNA), GRT-R912 (samRNA) and GRT-R918 (samRNA).

Price
Delayed
$2.74
Day's Change
-0.135 (-4.70%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.89
Day's Low
2.71
Volume
(Below Average)

Today's volume of 235,824 shares is on pace to be lower than GRTS's 10-day average volume of 536,990 shares.

235,824

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, December 05, 2022
November 21, 2022
November 17, 2022
November 10, 2022
November 03, 2022
October 25, 2022
October 19, 2022
October 17, 2022
September 20, 2022
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EQNX::TICKER_START (NASDAQ:GRTS), EQNX::TICKER_END Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the company's Board of Directors granted three...(Globe Newswire)

September 12, 2022
Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022

EQNX::TICKER_START (NASDAQ:GRTS), EQNX::TICKER_END /p>

-- Molecular response, as measured by reduction in circulating tumor DNA (ctDNA) from baseline, demonstrates a correlation with overall survival (OS) in NSCLC...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.